EDIT
Editas Medicine·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
MACD Golden Cross
Ample Liquidity
High Gross Profit Margin
Significant Revenue Decline
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About EDIT
Editas Medicine, Inc.
A leading genome editing company pioneering CRISPR technology for treating serious diseases
11 Hurley Street
, Cambridge
, Massachusetts 02141
--
Editas Medicine, Inc., was founded in September 2013 as Gengine, Inc., and later changed its name to Editas Medicine, Inc., in November 2013. The company is a leading genetic research company dedicated to treating gene-related diseases by correcting patients' disease-causing genes.
Company Financials
EPS
EDIT has released its 2025 Q3 earnings. EPS was reported at -0.28, versus the expected -0.38, beating expectations. The chart below visualizes how EDIT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
EDIT has released its 2025 Q3 earnings report, with revenue of 7.54M, reflecting a YoY change of 12265.57%, and net profit of -25.12M, showing a YoY change of 59.58%. The Sankey diagram below clearly presents EDIT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
